登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Her2 >HE2-H5287

Human Her2 / ErbB2 Protein, Twin-Strep Tag

分子别名(Synonym)

ERBB2,CD340,HER-2,neu,HER2,MLN19,NEU,NGL,TKR1

表达区间及表达系统(Source)

Human Her2 Protein, Twin-Strep Tag (HE2-H5287) is expressed from human 293 cells (HEK293). It contains AA Thr 23 - Thr 652 (Accession # P04626-1).

Predicted N-terminus: Thr 23

Request for sequence

蛋白结构(Molecular Characterization)

Her2 Structure

This protein carries a twin strep tag at the C-terminus.

The protein has a calculated MW of 72.4 kDa. The protein migrates as 90-115 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 0.1 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

Her2 SDS-PAGE

Human Her2 Protein, Twin-Strep Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

 

活性(Bioactivity)-ELISA

Her2 ELISA

Immobilized Human Her2 Protein, Twin-Strep Tag (Cat. No. HE2-H5287) at 0.05 μg/mL (100 μL/well) can bind Herceptin with a linear range of 0.4-3 ng/mL (QC tested).

Protocol

 
评论(0)
 
ACRO质量管理体系
 
 

背景(Background)

Human Epidermal growth factor Receptor 2 (HER2) is also called ERBB2, HER-2,HER-2 /neu, NEU, NGL,TKR1 and c-erb B2,and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in development, cancer, communication at the neuromuscular junction and regulation of cell growth and differentiation .

 

前沿进展

Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: a US real-world cohort study
Modi, Zhang, Byng et al
Breast Cancer Res Treat (2025)
Abstract: Real-world outcomes are poorly understood for patients with human epidermal growth factor receptor 2 (HER2)-low (immunohistochemistry 1+ or 2+ with negative in situ hybridization) metastatic breast cancer (mBC).Using for the first time a nationwide electronic health record-derived de-identified database, we assessed demographics, treatment patterns, and outcomes of patients with HER2-low mBC who previously received one line of chemotherapy in the metastatic setting. The post-chemotherapy line was termed the index line of therapy (LOT).3765 patients [hormone receptor (HR)-positive: 78.8%, HR-negative: 21.0%] met the inclusion criteria (1 January 2011-30 April 2023). 61.7% of HR-positive patients received endocrine therapy prior to the index LOT. The largest patient percentage received single-agent chemotherapy at the index and subsequent two LOTs. For the overall cohort, the median real-world time to treatment discontinuation/death was 4.1 months (95% CI: 3.9-4.2) and the median real-world time to next treatment/death was 5.1 months (95% CI: 4.8-5.3) from the index LOT. Median real-world overall survival (all patients) was 15.8 months (95% confidence interval: 15.2-16.5, median follow-up = 54.5 months) from the index LOT.These data highlight the unmet clinical needs of patients with HER2-low mBC by characterizing the treatment patterns and poor outcomes in this population on the current standard of care.© 2025. The Author(s).
Digital mammography with AI-based computer-aided diagnosis to predict neoadjuvant chemotherapy response in HER2-positive and triple-negative breast cancer patients: comparison with MRI
Kim, Choi, Chi et al
Eur Radiol (2025)
Abstract: To investigate whether digital mammography (DM) with artificial intelligence-based computer-aided diagnosis (AI-CAD) predicts pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in human epidermal growth factor receptor 2 (HER2)-positive and triple-negative (TN) breast cancers and compare performance with dynamic contrast-enhanced (DCE)-MRI.In this single-center study, patients who underwent NAC and surgery for HER2-positive or TN cancers between September 2020 and August 2021 were retrospectively selected to develop prediction models for pCR after NAC. From a prospective ASLAN (Avoid axillary Sentinel Lymph node biopsy After Neoadjuvant chemotherapy) trial, HER2-positive and TN cancer patients who underwent NAC and surgery between December 2021 and July 2022 were prospectively selected for model validation. Clinical-pathologic data and DM and MRI scans were obtained before and after NAC. Logistic regression analyses identified factors associated with pCR for model development and four models (clinical-pathologic, MRI, DM-AI-CAD, and combined) were evaluated.A total of 259 women (mean age, 53 years ± 10.5 [SD]) constituted the development cohort and 119 (50.8 years ± 11.1) the validation cohort. Age, clinical N stage, estrogen receptor, progesterone receptor, and Ki-67 were incorporated into the clinical-pathologic model. In the validation cohort, the DM-AI-CAD model, applying AI-CAD score ≤ 16 on post-NAC DM as the radiologic CR criterion, showed a higher area under the receiver operating characteristic curve (AUC) compared to the clinical-pathologic model (0.72 vs. 0.62; p = 0.01) for pCR. However, the MRI model showed the highest AUC (0.83), then the combined model (0.78).The model utilizing post-NAC DM with AI-CAD score ≤ 16 predicted pCR more accurately than the clinical-pathologic model in HER2-positive and TN cancers but was inferior to the MRI model.Question The performance of digital mammography (DM) with AI-based computer-aided diagnosis (AI-CAD) for predicting pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) is unclear. Findings The DM-AI-CAD model incorporating AI-CAD score ≤ 16 on post-NAC DM predicted pCR more accurately than the clinical-pathologic model but not the MRI model. Clinical relevance The DM-AI-CAD model has potential to predict pCR after NAC in breast cancer patients for whom MRI is unavailable or contraindicated.© 2025. The Author(s), under exclusive licence to European Society of Radiology.
Efficacy of disitamab vedotin-containing therapy in metastatic colorectal cancer: A case report
Yan, Liu, Feng et al
World J Clin Oncol (2025) 16 (3), 99527
Abstract: Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. In cases of metastatic CRC (mCRC) that are resistant to conventional chemotherapy-based treatments, the efficacy of available therapeutic options is typically low. CRC exhibiting overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) gene has shown responsiveness to HER2-targeted therapies.We present the case of a 69-year-old woman diagnosed with mCRC with an NRAS p.G12V mutation and microsatellite stability, identified through tumor sequencing, along with HER2 overexpression detected by immunohistochemistry. She exhibited an excellent response to disitamab vedotin-containing therapy. To our knowledge, this is the first reported case of mCRC with HER2 overexpression and an NRAS p.G12V mutation achieving a remarkable clinical response to anti-HER2 therapy.Disitamab vedotin demonstrates promising anti-tumor effects in HER2-overexpressing mCRC, offering patients an additional treatment option.©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Showing 1-4 of 46208 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Her2靶点信息
英文全称:Receptor protein-tyrosine kinase erbB-2
中文全称:受体蛋白酪氨酸激酶 erbB-2
种类:Homo sapiens
上市药物数量:39详情
临床药物数量:201详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定